[HTML][HTML] Electrochemical separation and purification of no-carrier-added 177Lu for radiopharmaceutical preparation: Translation from bench to bed
The entry of no-carrier-added (NCA) 177 Lu in the arena of clinical nuclear medicine has
revolutionized the practice of targeted radionuclide tumor therapy. In this study, we report the …
revolutionized the practice of targeted radionuclide tumor therapy. In this study, we report the …
[HTML][HTML] Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model
Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA)-targeted
radiopharmaceutical therapy is a clinically approved treatment for patients with metastatic …
radiopharmaceutical therapy is a clinically approved treatment for patients with metastatic …
[HTML][HTML] Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer
J Heilinger, J Weindler, KS Roth, P Krapf… - EJNMMI research, 2023 - Springer
Abstract Background In 2022, the American Food and Drug Administration and the
European Medicines Agency approved [177Lu] Lu-PSMA-617 (PLUVICTO™, Novartis AG …
European Medicines Agency approved [177Lu] Lu-PSMA-617 (PLUVICTO™, Novartis AG …
Investigation of imaging the somatostatin receptor by opening the blood-brain barrier with melittin–A feasibility study using positron emission tomography and [64Cu] …
IV Andersen, NSR Bidesi, V Shalgunov… - Nuclear Medicine and …, 2024 - Elsevier
DOTATATE is a somatostatin peptide analog used in the clinic to detect somatostatin
receptors which are highly expressed on neuroendocrine tumors. Somatostatin receptors …
receptors which are highly expressed on neuroendocrine tumors. Somatostatin receptors …
Threshold for defining PSMA-positivity prior to. sup. 177Lu-PSMA therapy: a comparison of [. sup. 68Ga] Ga-PSMA-11 and [. sup. 18F] F-DCFPyL in metastatic prostate …
J Heilinger, J Weindler, KS Roth, P Krapf… - EJNMMI …, 2023 - go.gale.com
Background In 2022, the American Food and Drug Administration and the European
Medicines Agency approved [. sup. 177Lu] Lu-PSMA-617 (PLUVICTO [TM], Novartis AG …
Medicines Agency approved [. sup. 177Lu] Lu-PSMA-617 (PLUVICTO [TM], Novartis AG …
Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium‐177 prostate‐specific membrane antigen …
JE Zoberi, J Garcia‐Ramirez… - Journal of applied …, 2023 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is a cell surface protein highly expressed in
nearly all prostate cancers, with restricted expression in some normal tissues. The …
nearly all prostate cancers, with restricted expression in some normal tissues. The …
Intraindividueller Vergleich der Biodistribution von [68Ga] Ga-PSMA-11 und [18F] F-DCFPyL im theranostischen Kontext
J Heilinger - 2023 - kups.ub.uni-koeln.de
Aufgrund der in den letzten Jahren voranschreitenden Entwicklung moderner für die
molekulare Bildgebung und Therapie geeigneter Radiopharmaka gewann die …
molekulare Bildgebung und Therapie geeigneter Radiopharmaka gewann die …
Theranostics: The Future is Now!
KS Thomas - Journal of Nuclear Medicine Technology, 2022 - Soc Nuclear Med
Overall, in the past 501 years, the diagnostic and therapeutic capabilities of nuclear
medicine and molecular imaging have significantly advanced thanks to the constant …
medicine and molecular imaging have significantly advanced thanks to the constant …